Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have been assigned an average recommendation of “Buy” from the ten brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $59.22.

A number of equities research analysts have weighed in on the company. Wedbush boosted their price objective on Vera Therapeutics from $30.00 to $38.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. Wells Fargo & Company assumed coverage on shares of Vera Therapeutics in a research note on Thursday, November 21st. They set an “overweight” rating and a $70.00 price target for the company. JPMorgan Chase & Co. lifted their price objective on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Cantor Fitzgerald reiterated an “overweight” rating and set a $107.00 target price on shares of Vera Therapeutics in a research note on Tuesday, October 1st. Finally, Evercore ISI upgraded Vera Therapeutics to a “strong-buy” rating in a research report on Monday, September 16th.

Vera Therapeutics Stock Up 1.9 %

Shares of NASDAQ VERA opened at $49.75 on Monday. The stock has a market cap of $3.15 billion, a P/E ratio of -19.06 and a beta of 1.03. The business’s fifty day simple moving average is $44.21 and its 200-day simple moving average is $39.77. Vera Therapeutics has a 12-month low of $13.07 and a 12-month high of $51.61. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.21). As a group, equities analysts predict that Vera Therapeutics will post -2.89 EPS for the current fiscal year.

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, Director Beth C. Seidenberg sold 1,177 shares of the business’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total transaction of $49,445.77. Following the sale, the director now directly owns 160,376 shares in the company, valued at approximately $6,737,395.76. The trade was a 0.73 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marshall Fordyce sold 23,125 shares of the business’s stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $46.05, for a total value of $1,064,906.25. Following the sale, the chief executive officer now directly owns 307,972 shares in the company, valued at approximately $14,182,110.60. The trade was a 6.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 89,927 shares of company stock worth $3,800,796 in the last ninety days. 21.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Vera Therapeutics

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in shares of Vera Therapeutics by 31.5% in the first quarter. Vanguard Group Inc. now owns 2,148,714 shares of the company’s stock worth $92,653,000 after buying an additional 515,106 shares during the period. California State Teachers Retirement System boosted its stake in Vera Therapeutics by 18.7% in the 1st quarter. California State Teachers Retirement System now owns 32,359 shares of the company’s stock worth $1,395,000 after purchasing an additional 5,088 shares during the period. Virtu Financial LLC purchased a new position in Vera Therapeutics during the 1st quarter worth approximately $375,000. Cetera Advisors LLC acquired a new stake in Vera Therapeutics during the 1st quarter valued at $235,000. Finally, William Marsh Rice University purchased a new stake in shares of Vera Therapeutics in the second quarter valued at $593,000. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.